MedTrace Logo

A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

NCT04435431 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2024-03-06

Study results available
· View outcomes & findings →

Summary

This is a Phase 2b study investigating the efficacy and safety of mesdopetam as adjunct therapy on daily ON-time without troublesome dyskinesia in patients with Parkinson disease. Mesdopetam is taken for 84 days.

Conditions

  • Parkinson Disease

Interventions

DRUG

Mesdopetam

Oral use

DRUG

Placebo

Oral use

Sponsors & Collaborators

  • Integrative Research Laboratories AB

    lead INDUSTRY

Principal Investigators

  • Joakim Tedroff · Integrative Research Laboratories AB (IRLAB)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-29
Primary Completion
2022-12-02
Completion
2022-12-09
FDA Drug
Yes

Countries

  • United States
  • France
  • Israel
  • Italy
  • Poland
  • Serbia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04435431 on ClinicalTrials.gov